Edgewise Therapeutics shares tumbled more than 20% Wednesday after the developmental drug company issued the results of its ...

Edgewise Therapeutics (NASDAQ:EWTX – Get Free Report) was downgraded by research analysts at Scotiabank from a “sector outperform” rating to a “sector perform” rating in a research report issued on ...

Discover growth opportunities with Edgewise Therapeutics, Inc. in the hypertrophic cardiomyopathy market. Click for my EWTX ...

Colorado-based Edgewise Therapeutics, a muscle disease-focused biopharma company, closed 23% lower after Wednesday’s trading.

As previously reported yesterday, Scotiabank downgraded Edgewise Therapeutics (EWTX) to Sector Perform from Outperform with a price target of ...

Shares of Edgewise Therapeutics and Cytokinetics diverged Wednesday after safety questions highlighted a heart disease study from Edgewise.

Across the study, two patients experienced “serious adverse events of atrial fibrillation (AF) requiring cardioversion,” ...

Cytokinetics (NASDAQ:CYTK) added ~10% in the premarket on Wednesday after its rival Edgewise Therapeutics (NASDAQ:EWTX) ...

Edgewise Therapeutics, Inc.’s EWTX share price has dipped by 28.51%, which has investors questioning if this is right time to buy.

Piper Sandler analyst Yasmeen Rahimi remains bullish on Edgewise Therapeutics (EWTX) and maintains an Overweight rating and $51 price target on ...

Edgewise Therapeutics (EWTX) stock drops 17% after Scotiabank downgrades rating and cuts price target to $14. Read more here.

This is a disease where the heart muscle gets thicker, which can block blood flow and cause heart failure. The company revealed some good results from the study, but Scotiabank pointed out some ...